Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

28,775 28,651 28,734 28,637

(1) Includes $- and $77 as additional research and development expense,

which represents an estimate of the net payable due to Novartis of

ANA975 research and development costs for the three months ended

September 30, 2008 and 2007, respectively. Includes ($47) and ($514)

as an offset in research and development expense, which represents an

estimate of the net reimbursement by Novartis of ANA975 research and

development costs for the nine months ended September 30, 2008 and

2007, respectively.

(2) Includes non-cash operating expenses of $738 and $1,392 determined in

accordance with Statement of Financial Accounts Standards No. 123(R),

"Share-Based Payment" (SFAS No. 123(R)) or approximately $0.03 and

$0.05 effect on basic and diluted net (loss) income per common share

for the three months ended September 30, 2008 and 2007, respectively.

Research and development expense and general and administrative

expense includes $326 and $412 of non-cash operating expenses

determined in accordance with SFAS No. 123(R) for the three months

ended September 30, 2008. Includes non-cash operating expenses of

$2,065 and $3,502 determined in accordance with SFAS No. 123(R) or

approximately $0.07 and $0.12 effect on basic and diluted net loss per

common share for the nine months ended September 30, 2008 and 2007,

respectively. Research and development expense and general and

administrative expense includes $949 and $1,116 of non-cash operating

expenses determined in accordance with SFAS No. 123(R) for the nine

months ended September 30, 2008.

Anadys Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(In thousands)


'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Axovant Sciences Ltd. (NYSE:  AXON), a leading clinical-stage ... upcoming presentations at three investor conferences: , Wednesday, ... Conference in New York at the ... 2:00 PM at the BioCentury NewsMakers Conference in ... Conference Center , Thursday, September 17 at 9:30 AM ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... managed with the use of special anti-vascular endothelial growth factor agents given by ... patients, currently does not have a scientific protocol for the many millions diagnosed ...
(Date:9/2/2015)... ... 02, 2015 , ... Drug companies increasingly are adopting a ... reveals in its new report that the U.S. will generate the greatest demand ... the most market demand. , BCC Research examines plant-derived drugs in its ...
(Date:9/2/2015)... BioLight Life Sciences Investments ... a firm that invests in, manages and commercializes ... today that presentations highlighting its IOPtiMate™ system for ... the Ophthalmology Futures European Forum and the XXXIII ... Refractive Surgeons ("ESCRS"), both taking place in the ...
Breaking Biology Technology:Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... ... distribute feedstock for E-Fuel MicroFueler™ , ... Sacramento (Vocus) June 4, 2009 -- California Governor Arnold Schwarzenegger joined ... Corp. unveiled the final production model of the revolutionary E-Fuel MicroFueler, a portable micro-refinery ...
... WEBCAST WEDNESDAY, JUNE 10, 2009 , , SAN ... NBIX ) announced today that Kevin Gorman, President and Chief ... 8th Annual Needham Life Sciences Conference in New York. ... 10, 2009 at 1:30 p.m. Eastern Time (ET)/10:30 a.m. Pacific ...
... , BRAINTREE, Mass., June 4 Haemonetics Corporation (NYSE: ... for the District of Massachusetts has made a ruling in ... January 2009, a jury issued a verdict in favor of ... a U.S. Haemonetics patent. The jury awarded Haemonetics $15.7 ...
Cached Biology Technology:GreenHouse Energy, Governor Schwarzenegger Join in Driving the Future of Fueling in California 2GreenHouse Energy, Governor Schwarzenegger Join in Driving the Future of Fueling in California 3Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference 2Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology 2
(Date:8/20/2015)... , Aug. 20, 2015 The wearable ... that are active and healthy. However, wearable technology ... hospital environment to help improve diagnostic capabilities and ... from the Wearable Technologies Conference 2015 , ... applications for wearables in healthcare.    ...
(Date:8/18/2015)... 2015  Navitas today announced that it ... Submission Content Management webinar scheduled on August ... to the Implementation of Regulatory Submission Standards ... industry, vendors, health authorities, consultants and the ... a standard method of implementing electronic submission ...
(Date:8/12/2015)... 12, 2015 As the digital ... innovation and advanced biometrics technology is accelerating beyond expectations.  ... rely on using their credit cards, the digital currency, ... for payment services led by companies in the space ... Google, Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... at Iowa State University have discovered a previously unknown ... Yanhai Yin, an assistant professor in genetics, development and ... called brassinosteroids. The hormone controls the growth of cells. ... how large the plant grows, says Yin. , "Previously, ...
... the oldest synthetic malaria drug, the methylene blue stain, ... a significant contribution to the long-term eradication called for ... study on 160 children with malaria in Burkina Faso, ... have shown that in combination with newer malaria drugs, ...
... Some researchers hope to turn plants into a renewable, ... have to learn how to convert plant biomass into ... efficiently. In new research, chemists have successfully converted cellulose ... the building block called HMF in one step. ...
Cached Biology News:ISU researcher identifies genetic pathway responsible for much of plant growth 2Old stain in a new combination 2Old stain in a new combination 3Plastic that grows on trees, part two 2
... cultured in RPMI 1640 with 2 mM L-glutamine ... In order to keep the antigens in ... The cells are arrayed on a 12-well ... surface specifically treated to enhance cellular attachment and ...
... proteases/caspases initiates apoptosis in mammalian cells. ... provides a simple and convenient means for ... in intact cells. The assay utilizes ... linked to rhodamine 110 (D2R), a reported ...
... NovaTaq DNA Polymerase is a premium ... polymerase. This thermostable enzyme is suitable for ... ensure the highest purity and reproducible performance, ... variety of quality control assays. NovaTaq DNA ...
BD Falcon insert HTS 96 well, square A-bottom with lid. PET membrane, sterile. (5/ca) Packaging: 5 / pack, 5 / case ...
Biology Products: